期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

DNA拓扑异构酶IIα(topo IIα)与乳腺癌蒽环类药物化疗敏感性的研究进展 被引量：10

The research progress of the association between DNA topoisomerase IIα(topo IIα) and sensitivity to chemotherapy for breast cancer
下载PDF
导出
摘要 DNA拓扑异构酶IIα(topoisomerase IIα,topo IIα)不仅是肿瘤细胞的一个增殖指标,也是蒽环类化疗药物的治疗靶点。体外实验已经表明topo IIα表达水平与蒽环类药物敏感性有关,但topo IIα能否作为乳腺癌蒽环类化疗敏感性的预测因子还存在争论。本文就近年来topo IIα及其他相关的分子指标与乳腺癌蒽环类药物敏感性的研究进展作一综述。 Topoisomerase Ⅱa （topo Ⅱa） is not only a target for anthracycline-based chemotherapy. In vitro proliferation marker of tumor cells but also a studies have shown that there is relationship between topo Ⅱa expression level and chemosensitivity to anthracyclines. However there are several controversies on the role of topo Ⅱa in predicting sensitivity to anthracycline-based chemotherapy for breast cancer in clinical studies. We aim to give a review of the research advances on the association between topo Ⅱa with other related biomarkers and the sensitivity of anthracycline-based chemotherapy in breast cancer patients.
作者 杜跃耀(综述) 殷文瑾 陆劲松(审校)
机构地区 复旦大学附属肿瘤医院乳腺外科-复旦大学上海医学院肿瘤学系
出处 《复旦学报（医学版）》 CAS CSCD 北大核心 2012年第2期203-206,共4页 Fudan University Journal of Medical Sciences
关键词 DNA拓扑异构酶Ⅱa(topo Ⅱa) Her-2-p53 17号染色体 蒽环类药物 预测因子 乳腺癌 topoisomerase Ⅱa （ topo Ⅱa） Her-2-p53 chromosome 17 anthracyclines predictive factor breast cancer
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献22

  • 1Berger JM,Gamblin SJ,Harrison SC,et al.Structure andmechanism of DNA topoisomerase Ⅱ[J].Nature,1996,379(6562):225-232.
  • 2Kellner U,Sehested M,Jensen PB,et al.Culprit andvictim-DNA topoisomerase Ⅱ[J].Lancet Oncol,2002,3(4):235-243.
  • 3Durbecq V,Paesmans M,Cardoso F,et al.Topoisomerase-II alpha expression as a predictive marker in a populationof advanced breast cancer patients randomly treated eitherwith single-agent doxorubicin or single-agent docetaxel[J].Mol Cancer Ther,2004,3(10):1207-1214.
  • 4Di LA,Gancberg D,Larsimont D,et al.HER-2amplification and topoisomerase Ⅱalpha gene aberrationsas predictive markers in node-positive breast cancerpatients randomly treated either with an anthracycline-based therapy or with cyclophosphamide,methotrexate,and 5-fluorouracil[J].Clin Cancer Res,2002,8(5):1107-1116.
  • 5Jarvinen TA,Tanner M,Rantanen V,et al.Amplificationand deletion of topoisomerase Ⅱalpha associate with ErbB-2amplification and affect sensitivity to topoisomerase Ⅱinhibitor doxorubicin in breast cancer[J].Am J Pathol,2000,156(3):839-847.
  • 6Desmedt C,Azambuja E,Larsimont D,et al.Predictingthe efficacy of anthracyclines in breast cancer(BC)patients:Results of the neoadjuvant TOP trial[J].J ClinOncol,2009,27(15):523.
  • 7Di Leo A,Isola J,Piette F,et al.A meta-analysis of phaseⅢ trials evaluating the predictive value of HER2andtopoisomerase Ⅱ alpha in early breastcancer patientstreated with CMF or anthracycline-based adjuvant therapy[C].Presented at the 2008annual San Antonio BreastCancer Symposium.
  • 8Bartlett JMS,Munro A,Dunn JA,et al.Chromosome 17polysomy(Ch17)as a predictor of anthracyclineresponse:emerging evidence from the UK NEAT adjuvantbreast cancer trial[C].Presented at the 2008annual SanAntonio Breast Cancer Symposium.
  • 9Knoop AS,Knudsen H,Balslev E,et al.Retrospectiveanalysis of topoisomerase IIa amplifications and deletionsas predictive markers in primary breast cancer patientsrandomly assigned to cyclophosphamide,methotrexate,and fluorouracil or cyclophosphamide,epirubicin,andfluorouracil:Danish Breast Cancer Cooperative Group[J].J Clin Oncol,2005,23(30):7483-7490.
  • 10O’Malley FP,Tu SCD,Shepherd LE,et al.Topoisomerase Ⅱ alpha and responsiveness of breastcancer to adjuvant chemotherapy[J].J Natl Cancer Inst,2009,101(9):644-650.

同被引文献108

  • 1赵晓东,张毅.常规化疗药物疗效预测分子与化疗选药[J].癌症,2006,25(12):1577-1580. 被引量：13
  • 2孙强.乳腺癌的早期诊断[J].实用医学杂志,2007,23(1):1-3. 被引量：77
  • 3徐兵河.蒽环类耐药性乳腺癌的治疗策略[J].中华肿瘤杂志,2007,29(4):241-244. 被引量：85
  • 4孙菊杰,仲伟霞,张德贤,穆殿斌,原银萍.食管鳞癌组织中肺耐药蛋白表达和DNA含量的定量分析[J].中华肿瘤防治杂志,2007,14(12):920-923. 被引量：3
  • 5OConnor JK, Hazard LJ,Avent JM, et al. Topoisomerase Ⅱ alpha Expression correlates with diminished disease-free survival in invasive breast cancer [J ] Int J Radiat Oncol Biol Phys ,2006,65 ( 5 ) : 1411.
  • 6Petit T, Wilt M, Vehen M, et al. Comparative value of turn- our grade, hormonal receptors, Ki-67, HER-2 and topoi- somerase 1] alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracy cline- based chemotherapy[ J]. Eur J Cancer,2010,40(2):205.
  • 7Masuda H, Masuda N, Kodama Y, et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prog- nosis in triple-negative breast cancer patiets [ J ]. Cancer Chemother Pharmaco1,2011,67 (4) :911.
  • 8Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of all immunohistochemieal definition in the BCIRG 001 trial[ J ]. J Clin 0ncol,2009,27 ($) : 1168.
  • 9Lichtman SM, Wildiers H, Chatelut E, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: e- valuation of chemotherapy in older patients-ananalysis of the medical literature [ J]. J Clin Oncol, 2007,25 ( 14 ) : 1832.
  • 10Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours [ J ] Nature,2010,406 ( 6797 ) :747.

引证文献10

二级引证文献86

复旦学报（医学版）
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部